Immunofluorescence revealed that pharmacologic inhibition of oncogenic MAPK signaling reduces DRP1-S616P levels, which correlates with mitochondrial hyperfusion, while immunohistochemistry showed that elevated DRP1-S616P expression in human tissues correlates with BRAF<sup>V600E</sup> disease.<h4>Conclusions</h4>3G11 is a new recombinant antibody for detecting DRP1-S616P and supports studies of mitochondrial division in cancer. This evidence concerns the gene DNM1L and cancer.